Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueInventory Average

RedHill Biopharma (RDHL) Gross Margin (2016 - 2023)

Historic Gross Margin for RedHill Biopharma (RDHL) over the last 9 years, with Q2 2023 value amounting to 55.12%.

  • RedHill Biopharma's Gross Margin rose 41500.0% to 55.12% in Q2 2023 from the same period last year, while for Jun 2023 it was 42.74%, marking a year-over-year increase of 11100.0%. This contributed to the annual value of 60.31% for FY2024, which is 132800.0% up from last year.
  • According to the latest figures from Q2 2023, RedHill Biopharma's Gross Margin is 55.12%, which was up 41500.0% from 55.21% recorded in Q1 2023.
  • RedHill Biopharma's 5-year Gross Margin high stood at 75.99% for Q1 2019, and its period low was 62.41% during Q1 2020.
  • Moreover, its 5-year median value for Gross Margin was 50.7% (2020), whereas its average is 43.77%.
  • In the last 5 years, RedHill Biopharma's Gross Margin tumbled by -1384000bps in 2020 and then soared by 1125700bps in 2021.
  • Over the past 5 years, RedHill Biopharma's Gross Margin (Quarter) stood at 50.44% in 2019, then decreased by 0bps to 50.37% in 2020, then crashed by -75bps to 12.4% in 2021, then surged by 165bps to 32.82% in 2022, then surged by 68bps to 55.12% in 2023.
  • Its last three reported values are 55.12% in Q2 2023, 55.21% for Q1 2023, and 32.82% during Q4 2022.